Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOXF.L Regulatory News (OXF)

  • There is currently no data for OXF

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Report & Accounts

20 May 2008 11:34

RNS Number : 8621U
Oxford Technology 4 VCT PLC
20 May 2008
 

Preliminary Announcement for

 Oxford Technology 4 Venture Capital Trust plc for the year ended 

29 February 2008

Chairman's Statement

Investment Portfolio

The Board of Oxford Technology 4 VCT is pleased with the development of the portfolio as a whole. However, the overall result is a mixture, with some companies making good progress while others have experienced problems of one sort or another.

 

Ultimately, success for OT4 as a whole, meaning a good return to OT4 shareholders, is likely to come about because one or more of the investees become stars, and therefore very valuable. In other words, good returns are more likely to come from one or more 'stars' than from the fact that every company delivers good returns.

 

It is good to be able to report that many companies in the OT4 portfolio continue to have the potential to become stars. Included among these are the following:

 

Arecor, which is still at a very early stage, but which has made an encouraging start. OT4 owns 8.2%.

 

Diamond Hard Surfaces has achieved a significant milestone in its development in that it has received the first orders for components coated with its unique thick ultra-hard diamond coating, for use in an industrial application. It has also received the first repeat orders for this application. It continues to receive orders for samples for testing in new applications. OT4 owns 44.6%.

 

Glide Pharma continues to make good progress, and the first trials with the use of Glide for vaccines have showed significantly better results than when the same vaccines are injected using a conventional needle and syringe. Some of the world's largest pharmaceutical companies are now in active talks with Glide. At least two have asked for exclusivity over various products and product areas. Glide Pharma also won the Medical Futures Award in summer 2007. OT4 owns 13.5%.

 

Impact Applications (in which OT4 now owns 33.6%), after a period of rapid growth in the autumn, has had a few months of low sales, but the quotations outstanding total more than £3m at the time of writing, and the company is optimistic about its future.

 

OT4 owns 19.4% of Inscentinel. Inscentinel has yet to achieve its first commercial sales, but received a visit before Christmas from one of the world's largest defence companies which has expressed a desire to partner with Inscentinel, on developing bee-based systems for various security applications.

 

The regulatory process is notoriously slow, but Insense has at last received approval for the sale of the first of its range of active wound-healing dressings, Oxyzyme, which actively transports oxygen to the wound surface. The first sales of Oxyzyme were achieved in the UK and Europe in autumn 2007, and are now growing month by month. The results from the clinical trials, where Oxyzyme is being used on hard-to-heal wounds, continue to be very encouraging, with some persistent wounds which have remained raw for several years, being healed with dry skin forming in a matter of weeks. Sales of the second dressing in the range, Iodozyme which produces slow release iodine to deal with infected wounds, as well as producing oxygen, are expected to start in the spring, hopefully in the US as well as in Europe. But OT4 owns only a small shareholding.

 

OT4 owns 23.7% of Meciria, whose new directional drilling tool for use in oil wells has now been produced. Drilling tests aer planned for June 2008.

 

OT4 owns 8% of Mirriad, whose software enables products to be 'placed' in a video clip. A can of Coca Cola, for example may be inserted on a desk, when it was not there in the original, and will then appear, with the correct lighting, and casting a shadow appropriate to the lighting etc, throughout the clip. The film studios are very interested in this, since it enables product placement advertising to be sold globally. Trial contracts have been placed by the big film studios.

 

OT4 owns 7.9% of Novacta, which is making good progress with its programme to produce an antibiotic for C.diff. It recently received a commitment to invest up to £3.5m from the Wellcome Trust.

 

OT4 owns only 3.4% of Orthogem (OT2 owns a much larger shareholding), but Orthogem is making excellent progress. Its artificial bone graft, Tripore, is now being sold mainly for use in spinal surgery both in Europe and the US. A white paper giving the one year results of the first ten spinal patients has now been published. Orthogem has had expressions of interest to acquire the company.

 

OT4 owns 45.9% of Pharma Engineering. Pharma Engineering has achieved its first sales, and its equipment is in use in production environments. At the time of writing it has several orders and has a growing pipeline of potential customers. 

 

Plasma Antennas has now achieved its first sales (as distinct from R&D contracts of which it has had many). These were for directional steerable antennas for use in trials. If the trials are successful then larger contracts may be expected. Work on producing a plasma antenna continues, but this is a highly challenging technical task. OT4 owns 21.9% of Plasma Antennas.

 

OT4 owns 16.3% of Telegesis. Telegesis has achieved the first sales of its Zigbee modules and sales have been growing fast. Sales in the quarter to June 07 were £49k. Sales in the quarter to September were £165k. Sales in the quarter to December 2007 were £618k. At the time of writing it seems likely that sales in the quarter to March 08 will be slightly below those in the December quarter, but there is also the possibility of some much larger orders in the future.

 

All these companies have the potential to deliver very significant returns.

 

Other companies have had problems and their value has been written down. Net Assets per Share at 29 February 2008 were £1.08. This compares to £1.11 at 31 August 2007, and 91p at 28 February 2007.

 

 

 

 

 

Results for the year

 

Interest on bank deposits and investee loans together with dividend income produced gross revenue of £139,000 (2007: £192,000) in the year. 

 

Net revenue after taxation and management expenses was a loss of £150,000 (2007: loss of £176,000) and revenue return for the year was a loss of 1.45p (2007: loss of 1.81p) per share. 

 

Capital return was a gain of 18.58p per share (2007: loss of 3.09p).

 

 

 

 

 

AGM

 

Shareholders should note that the AGM for Oxford Technology 4 VCT will be held on Monday 23rd June 2008, at the Magdalen Centre, Oxford Science Park, starting at 12.00 noon and will include presentations by some of the companies in which the Oxford Technology VCTs have invested. A formal Notice of AGM has been included at the back of these Accounts together with a Form of Proxy for those not attending.

 

John Jackson

Chairman

9 May 2008

 

 

 

 

Statement of total return (incorporating the revenue account) for the year ended 29 February 2008

 

 

 

 

 

 

 

 

 

 

 Revenue

 Capital

2008 Total

Revenue

Capital

2007 Total

 

£000

£000

£000

£000

£000

£000

Gains/(losses) on investments

-

1,921

1,921

-

(301)

(301)

Income

139

-

139

192

-

192

Investment management fee

(227)

-

(227)

(231)

-

(231)

Other expenses

(62)

-

(62)

(137)

-

(137)

 

 

_____

_____

_____

_____

_____

_____

Net return/(loss) on ordinary activities before taxation

(150)

1,921

1,771

(176)

(301)

(477)

Tax on net return/(loss) on ordinary activities

-

-

-

-

-

-

Return/(loss) attributable to equity shareholders and transfers to/(from) reserves

(150)

1,921

1,771

(176)

(301)

(477)

 

 

 

 

 

 

 

 

_____

_____

_____

_____

_____

______

Return/(loss) per ordinary share

(1.45)p

18.58p

17.13p

(1.81)p

(3.09)p

(4.90)p

 

 

 

 

 

 

 

The revenue column of this statement is the profit and loss account of the company.

All revenue and capital items in the above statement derive from continuing operations. There were no recognised gains or losses for the period other than those shown above.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance sheet at 29 February 2008

 

 

29 February 2008 Audited 

28 February 2007 Audited 

 

£000

£000

£000

£000

Fixed assets

 

 

 

 

Investments at fair value

 

8,640

 

5,552

Current assets

 

 

 

 

Debtors & prepayments

385

 

25

 

Cash at bank

2,121

 

3,793

 

 

_____

 

_____

 

 

2,506

 

3,818

 

 

Creditors: amounts falling due within one year

(10)

 

(5)

 

 

_____

 

_____

 

Net current assets/liabilities

 

2,496

 

3,813

 

 

_____

 

_____

Net assets

 

11,136

 

9,365

 

 

=====

 

=====

Capital and reserves

 

 

 

 

Called up share capital

 

1,034

 

1,034

Share premium account

 

9,061

 

9,061

 

Other reserves:

 

 

 

 

Capital reserve - realised

 

318

 

-

Capital reserve - unrealised

 

1,217

 

(386)

Revenue reserve

 

(494)

 

(344)

 

 

 

 

 

Shareholders' funds

 

11,136

 

9,365

 

 

=====

 

=====

Net asset value per share

 

107.7p

 

90.6p

 

 

 

 

 

 

 

=====

 

=====

 

 

 

 

 

 

 

Cash flow statement for the year ended 29 February 2008

 

2008 Audited

2007 Audited

 

£000

£000

Net cash (outflow) from operating activities

(130)

(69)

Capital expenditure and financial investment

 

 

Purchase of investments

(1,710)

(2,303)

Disposal/redemption of investments

168

-

 

______

______

Net cash outflow from capital expenditure and financial investment

(1,672)

(2,303)

Net cash outflow before financing

(1,672)

(2,372)

 

 

Financing

 

 

Issue of shares

-

3,196

Expenses paid in connection with share issue

-

(42)

 

 

______

______

Net cash inflow from financing

-

3,154

 

______

______

Increase/Decrease in cash

(1,672)

782

 

=====

===== 

Notes:

1. Basis of preparation

The preliminary announcement has been prepared in accordance with applicable accounting standards and with the Statement of Recommended Practice 'Financial statements of investment trust companies' issued in December 2005. The principal accounting policies are set out in the company's financial statements for the year ended 29 Februrary 2008.

2. Return per Ordinary Share

The calculation of revenue return per share is based on the loss of £150,000 (2007: loss of £176,000) for the financial period divided by the weighted average number of ordinary shares of 10,339,702 (2007: 9,755,566) in issue during the period.

The calculation of capital return per share is based on the net capital return for the financial period of £1,921,000 (2007: loss of £301,000) divided by the weighted average number of ordinary shares of 10,339,702 (2007: 9,755,566) in issue during the period.

 

3. General

The financial information set out in this preliminary announcement does not constitute statutory accounts as defined in section 240 of the Companies Act 1985. The balance sheet at 29 February 2008 and the profit and loss account, cash flow statement and associated notes for the year then ended have been extracted from the company's 2008 statutory financial statements on which the auditors' opinion is unqualified and does not include any statement under section 237 of the Companies Act 1985.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR URARRWBRVUAR
12
Date   Source Headline
30th Jun 202212:15 pmGNWResult of Meeting and Merger Update
30th Jun 20227:00 amGNWTemporary Suspension
20th Jun 20223:48 pmGNWResult of Meeting
15th Jun 20227:00 amGNWTransaction in Own Shares
8th Jun 20229:22 amGNWStatement re Buyback
18th May 202212:33 pmGNWPublication of Prospectus
17th May 20226:43 pmGNWNet Asset Value(s)
22nd Apr 20227:00 amGNWNet Asset Value
22nd Apr 20227:00 amGNWUnaudited 12 Month Interim Report and Announcement of Buy Back
4th Mar 20227:00 amGNWMiscellaneous
3rd Mar 20229:51 amGNWMiscellaneous
24th Feb 20221:30 pmGNWNet Asset Value
7th Jan 20221:00 pmGNW3rd Quarter Results
24th Nov 20217:00 amGNWDirector Declaration
11th Oct 20217:00 amGNWHalf-year report
26th Aug 20214:00 pmGNWPurchase of Shares for Cancellation
25th Aug 20214:00 pmGNWProposals regarding the Sub-division and Reclassification of Share Capital
25th Aug 202111:13 amGNWResult of AGM
28th Jul 202112:00 pmGNWStrategy/Company/Operations Update
22nd Jul 20218:20 amGNWNotice of AGM and Shareholder Presentations
30th Jun 20214:00 pmGNW1st Quarter Results
30th Jun 20213:45 pmGNWAnnual Financial Report
7th Jun 20217:00 amGNWPortfolio Update
18th May 20217:00 amGNWPortfolio Update
18th Dec 20207:00 amGNW3rd Quarter Results
9th Oct 20207:00 amGNWHalf-year report
30th Jul 20207:00 amGNWDirector Declaration
10th Jul 20207:00 amGNWResult of AGM
9th Jul 20209:05 amRNSSecond Price Monitoring Extn
9th Jul 20209:00 amRNSPrice Monitoring Extension
6th Jul 20207:00 amGNWDividend Declaration
2nd Jul 20207:00 amGNWMiscellaneous
21st May 20207:00 amGNWNet Asset Value(s)
20th May 20207:00 amGNWAnnual Financial Report
15th Apr 20206:02 pmGNWForm 8.3 - Castleton Technology PLC
16th Feb 20207:58 pmGNWHolding(s) in Company
12th Dec 20197:00 amGNWOxford Technology 4 VCT Plc - 3rd Quarter Results
19th Sep 20197:00 amGNWOxford Technology 4 Venture Capital Trust Plc : Half-year report
4th Jul 201912:29 pmGNWOxford Technology 4 VCT Plc: AGM Results
3rd Jul 20197:00 amGNWOxford Technology 4 VCT Plc : Holding(s) in Company
3rd Jul 20197:00 amGNWOxford Technology 4 VCT Plc - 1st Quarter Results
22nd May 20197:00 amGNWAnnual Financial Report
4th Apr 20197:00 amGNWOxford Technology 4 Venture Capital Trust Plc: Dividend Declaration
17th Dec 20187:00 amGNW3rd Quarter Results
24th Oct 20187:00 amGNWHalf-year report
28th Jan 20165:26 pmRNSHolding(s) in Company
7th Jun 20103:54 pmRNSAnnual Financial Report
28th May 201012:48 pmRNSTotal Voting Rights
10th May 201010:41 amRNSListing of New Ordinary Shares
6th May 20102:13 pmRNSFurther on Allotment of New Shares
12

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.